Accumulating evidence shows a progressive decline in the efficacy of coronavirus disease
2019 (COVID‐19)(severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]) …

With the advent of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
pandemic, several vaccines have been developed to mitigate its spread and prevent …

Immune protection following either vaccination or infection with SARS-CoV-2 is thought to
decrease over time. We designed a retrospective study, conducted at Leumit Health …

Several studies reported on the humoral response in subjects having received the
BNT162b2 mRNA COVID-19 vaccine. However, data on the kinetics of antibodies 3 months …

Data about the long-term duration of antibodies after SARS-CoV-2 vaccination are still
scarce and are important to design vaccination strategies. In this study, 231 healthcare …

Objectives This study aimed to determine antibody responses in healthcare workers who
receive the BNT162b2 mRNA COVID-19 vaccine and identify factors that predict the …

Background The magnitude and durability of immune responses to coronavirus disease
2019 (COVID-19) mRNA vaccines remain incompletely characterized in the elderly …

Abstract The Elecsys® Anti-SARS-CoV-2 S immunoassay (Roche Diagnostics International
Ltd, Rotkreuz, Switzerland) has been developed for the detection of antibodies to the severe …

(1) Background: The evaluation of anti-spike protein receptor-binding domain (S-RBD)
antibodies represents a useful tool to estimate the individual protection against Severe …

The gut microbiome is intricately coupled with immune regulation and metabolism, but its
role in Coronavirus Disease 2019 (COVID-19) is not fully understood. Severe and fatal …